查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
瀰漫大B細胞淋巴瘤市場：全球及區域分析與預測（2025-2035）
市場調查報告書
商品編碼
1753875

瀰漫大B細胞淋巴瘤市場：全球及區域分析與預測（2025-2035）

Diffuse Large B-cell Lymphoma Market - A Global and Regional Analysis: Analysis and Forecast, 2025-2035
出版日期: | 出版商: BIS Research | 英文 100 Pages | 商品交期: 1-5個工作天內

價格

瀰漫大 B 細胞淋巴瘤 (DLBCL) 市場的主要驅動力之一是標靶治療的進步，尤其是 CAR-T 細胞療法和雙特異性抗體等免疫療法。

這些治療方法正在徹底改變復發或難治性瀰漫大B細胞淋巴瘤的治療，提供前所未有的高效個人化治療方案。 CAR-T細胞療法，例如Yescarta和Kymriah，在傳統化療無效的患者中，已取得顯著成功，實現了長期緩解，顯著改善了患者的預後和生存期。

隨著人們對免疫療法潛力的認知不斷提高，以及基因檢測和生物標記分析技術的進步，人們越來越需要根據患者腫瘤的個別特徵來客製化更精準的治療方案。這些進展不僅有助於提高存活率，也減少了與傳統化療相關的副作用，而這些正是進一步推動瀰漫大B細胞淋巴瘤 (DLBCL) 市場發展的關鍵因素。

此外，非何傑金氏淋巴瘤(NHL) 的發生率不斷上升，尤其是在老年人口中，這導致對先進治療方案的需求日益成長。隨著診斷工具的改進，更多患者能夠在早期得到診斷，瀰漫大B細胞淋巴瘤 (DLBCL) 的治療市場正在迅速擴張，這為製藥公司開發和商業化創新治療方法創造了機會。

儘管瀰漫大B細胞淋巴瘤（DLBCL）市場正在成長，但仍存在一些挑戰阻礙其充分發揮潛力。其中一項主要挑戰是治療費用高昂，尤其是CAR-T細胞療法和雙特異性抗體等先進治療方法，這些療法通常價格昂貴，並非所有患者都能負擔得起，尤其是在中低收入國家。這些治療的高昂費用給醫療保健系統帶來了沉重的負擔，並限制了患者獲得最具創新性的治療方法。

另一個挑戰是抗治療性和復發。儘管CAR-T療法和其他標靶治療在治療復發或難治性瀰漫大B細胞淋巴瘤方面取得了令人矚目的成功，但仍有一些患者經歷治療失敗或疾病復發。這凸顯了持續創新和開發能夠克服抗藥性並提供更持久療效的新治療方法的必要性。

此外，CAR-T療法相關的副作用，例如細胞激素釋放症候群 (CRS) 和神經毒性，也令人擔憂。雖然這些副作用可以透過適當的監控和護理來控制，但它們需要專門的醫療基礎設施，可能會阻礙其廣泛應用，尤其是在醫療條件較差的環境中。

延遲診斷仍然是一個持續的挑戰：許多瀰漫性大B細胞淋巴瘤 (DLBCL) 病例確診時已是晚期，限制了治療效果。許多症狀與其他侵襲性較低的疾病重疊，導致干預延誤，而早期發現仍然是一個重大障礙。

最後，基於分子分析和遺傳標記的個人化治療的複雜性是一個挑戰：雖然精準醫療具有巨大的潛力，但檢測可用性和對腫瘤異質性缺乏了解等問題使得難以始終為正確的患者匹配正確的治療。

本報告研究了全球瀰漫大 B 細胞淋巴瘤 (DLBCL) 市場，並總結了主要趨勢、市場影響因素分析、法律制度、臨床試驗分析、市場規模趨勢和預測、各個細分市場的詳細分析、地區/主要國家、競爭格局和主要企業的概況。

目錄

執行摘要

第1章全球瀰漫大B細胞淋巴瘤市場：產業展望

  • 市場趨勢
  • 法律規範
  • 流行病學分析
  • 臨床試驗分析
  • 市場動態
    • 影響分析
    • 市場促進因素
    • 市場挑戰
    • 市場機會

2. 全球瀰漫大B細胞淋巴瘤市場（按地區）

  • 北美洲
    • 主要發現
    • 市場動態
    • 市場規模及預測
  • 歐洲
    • 主要發現
    • 市場動態
    • 市場規模及預測
  • 亞太地區
    • 主要發現
    • 市場動態
    • 市場規模及預測

3. 全球瀰漫大B細胞淋巴瘤市場：競爭格局與公司概況

  • 關鍵策略和發展
    • M&A
    • 協同效應活動
    • 業務擴展和資金籌措
    • 產品發布和核准
    • 其他活動
  • 公司簡介
    • AbbVie Inc.
    • Merck KGaA
    • F. Hoffmann-La Roche AG
    • Johnson & Johnson (Janssen Pharmaceuticals, Inc.)
    • Denovo Biopharma, Inc.
    • Calithera Biosciences, Inc.
    • Biogen Inc.
    • Autolus Therapeutics plc
    • Allogene Therapeutics, Inc.
    • Novartis AG
    • Miltenyi Biomedicine GmbH
    • Regeneron Pharmaceuticals, Inc.
    • Debiopharm International SA
    • Seagen Inc.
    • Takeda Pharmaceutical Company Limited

第4章調查方法

Product Code: BHL3035SA

Global Diffuse Large B-cell Lymphoma Market, Analysis and Forecast: 2025-2035

Diffuse Large B-cell Lymphoma (DLBCL) is an aggressive and most common form of non-Hodgkin lymphoma (NHL), a cancer that originates in the lymphatic system, which is part of the body's immune system. Diffuse Large B-cell Lymphoma is characterized by the rapid and uncontrolled growth of large B-cells, a type of white blood cell that plays a key role in immune response by producing antibodies. These abnormal B-cells grow in a diffuse pattern, meaning they spread throughout the affected tissue, often involving lymph nodes, spleen, bone marrow, and other organs.

Diffuse Large B-cell Lymphoma typically presents as a fast-growing tumor, and the symptoms can vary depending on the area affected, but common symptoms include swollen lymph nodes, fever, night sweats, unexplained weight loss, and fatigue. If untreated, Diffuse Large B-cell Lymphoma can rapidly progress and affect vital organs, which can lead to organ failure.

Diffuse Large B-cell Lymphoma is most diagnosed in adults, particularly those over the age of 60, but it can also occur in younger individuals. Diagnosis is typically confirmed through biopsy of the affected lymph node or tissue, followed by immunohistochemistry and genetic tests to assess the characteristics of the lymphoma cells.

The treatment for diffuse Large B-cell Lymphoma typically includes chemotherapy (such as R-CHOP, which combines Rituximab with chemotherapy drugs) and immunotherapy. In cases where the disease is resistant to treatment or recurs, CAR-T cell therapy and bispecific antibodies are emerging as effective options.

With prompt diagnosis and treatment, many patients with Diffuse Large B-cell Lymphoma can achieve remission, but the disease remains aggressive, and early intervention is crucial for improving survival outcomes.

One of the key drivers of the Diffuse Large B-cell Lymphoma (DLBCL) market is the advancement in targeted therapies, particularly immunotherapies like CAR-T cell therapy and bispecific antibodies. These therapies are revolutionizing the treatment of relapsed or refractory diffuse Large B-cell Lymphoma, offering highly effective and personalized treatment options that were previously unavailable. CAR-T cell therapies such as Yescarta and Kymriah have shown remarkable success in achieving long-term remission in patients who have failed conventional chemotherapy, significantly improving patient outcomes and survival rates.

The growing recognition of immunotherapy's potential, combined with advancements in genetic testing and biomarker profiling, is driving the demand for more precise treatment options tailored to the individual characteristics of patients' tumors. These advancements are not only improving survival rates but also reducing the side effects associated with traditional chemotherapy, which remains a critical factor in driving the Diffuse Large B-cell Lymphoma market forward.

Furthermore, the increasing prevalence of non-Hodgkin lymphoma (NHL), especially in the aging population, is contributing to the rising demand for advanced treatment options. As more patients are diagnosed at earlier stages due to improved diagnostic tools, the Diffuse Large B-cell Lymphoma market for Diffuse Large B-cell Lymphoma therapies is expanding rapidly, creating opportunities for pharmaceutical companies to develop and commercialize innovative treatments.

Despite the growth of the Diffuse Large B-cell Lymphoma (DLBCL) market, several challenges continue to impede its full potential. One of the primary challenges in Diffuse Large B-cell Lymphoma market is the high cost of treatment, particularly with advanced therapies like CAR-T cell therapy and bispecific antibodies, which are often expensive and may not be accessible to all patients, especially in low- and middle-income countries. The cost of these therapies places a significant burden on healthcare systems and limits patient access to the most innovative treatment options.

Another challenge is treatment resistance and relapse. While CAR-T therapies and other targeted treatments have shown impressive results in treating relapsed or refractory Diffuse Large B-cell Lymphoma, a subset of patients still experience treatment failure or disease recurrence. This highlights the need for continuous innovation and the development of additional therapies that can overcome resistance and provide more durable responses.

Additionally, side effects from treatments, including cytokine release syndrome (CRS) and neurological toxicities associated with CAR-T therapies, remain a concern. Although these side effects are manageable with proper monitoring and care, they require specialized healthcare infrastructure, which can be a barrier to widespread adoption, especially in less-equipped healthcare settings.

Late diagnosis is another ongoing issue, as many Diffuse Large B-cell Lymphoma cases are diagnosed at advanced stages, limiting the effectiveness of treatment. Early detection remains a significant hurdle, as many of the symptoms overlap with other, less aggressive conditions, delaying intervention.

Finally, the complexity of personalized treatment based on molecular profiling and genetic markers presents challenges. While precision medicine offers significant potential, there are issues related to the availability of testing and the understanding of tumor heterogeneity, making it difficult to always match the right treatment to the right patient.

Diffuse Large B-cell Lymphoma market challenges highlight the need for continued innovation, affordable access, and better healthcare infrastructure to fully realize the potential of Diffuse Large B-cell Lymphoma treatments and improve patient outcomes.

The global Diffuse Large B-cell Lymphoma (DLBCL) market is highly competitive, with several key players driving innovation and market growth. Leading companies such as AbbVie Inc. (Genmab A/S), Merck KGaA, F. Hoffmann-La Roche AG, and Johnson & Johnson (Janssen Pharmaceuticals, Inc.) are at the forefront, developing cutting-edge therapies to address the unmet needs of Diffuse Large B-cell Lymphoma patients. These companies are focusing on novel treatment approaches like CAR-T cell therapies, bispecific antibodies, and monoclonal antibodies that are showing significant promise in improving patient outcomes, particularly in relapsed or refractory cases. Additionally, companies like Biogen Inc., Novartis AG, and Regeneron Pharmaceuticals, Inc. are investing heavily in immunotherapies and targeted treatments, which are reshaping the treatment landscape and expanding the scope for long-term remission and improved survival rates. The ongoing research and strategic partnerships within these companies are driving continued advancements in the Diffuse Large B-cell Lymphoma market, contributing to a growing demand for more personalized, effective, and less toxic treatment options. As the Diffuse Large B-cell Lymphoma market continues to evolve, these leaders remain integral in providing innovative therapies for better management of Diffuse Large B-cell Lymphoma.

Diffuse Large B-cell Lymphoma Market Segmentation:

Segmentation 1: by Region

  • North America
  • Europe
  • Asia-Pacific

The global Diffuse Large B-cell Lymphoma (DLBCL) market is experiencing several key emerging trends that are reshaping the landscape of diagnosis, treatment, and patient care. One of the most significant trends in Diffuse Large B-cell Lymphoma market is the increasing focus on immunotherapy, particularly CAR-T cell therapy and bispecific antibodies. These therapies represent a shift towards targeted and personalized treatments, offering improved efficacy in relapsed or refractory Diffuse Large B-cell Lymphoma cases where traditional chemotherapy has often failed. CAR-T therapies, such as Yescarta and Kymriah, are showing promising results in inducing long-term remissions and are becoming an integral part of the Diffuse Large B-cell Lymphoma treatment landscape.

Another emerging trend is the growing emphasis on combination therapies, where immunotherapy is used in conjunction with chemotherapy or other targeted therapies. This approach aims to enhance treatment effectiveness by addressing multiple pathways that contribute to disease progression. Bispecific antibodies like epcoritamab, which target both CD3 on T-cells and CD20 on B-cells, are gaining momentum due to their ability to more effectively engage the immune system and directly target lymphoma cells.

Additionally, the focus on personalized medicine is reshaping the treatment approach for Diffuse Large B-cell Lymphoma. Advances in genetic profiling and biomarker testing are allowing clinicians to better understand the molecular characteristics of individual patients' tumors, enabling the selection of therapies tailored to the specific needs of the patient. This trend towards precision medicine is leading to more effective and less toxic treatments, improving patient outcomes.

Table of Contents

Executive Summary

Scope and Definition

Market/Product Definition

Inclusion and Exclusion

Key Questions Answered

Analysis and Forecast Note

1. Global Diffuse Large B-cell Lymphoma Market: Industry Outlook

  • 1.1 Introduction
  • 1.2 Market Trends
  • 1.3 Regulatory Framework
  • 1.4 Epidemiology Analysis
  • 1.5 Clinical Trial Analysis
  • 1.6 Market Dynamics
    • 1.6.1 Impact Analysis
    • 1.6.2 Market Drivers
    • 1.6.3 Market Challenges
    • 1.6.4 Market Opportunities

2. Global Diffuse Large B-cell Lymphoma Market (Region), ($Billion), 2023-2035

  • 2.1 North America
    • 2.1.1 Key Findings
    • 2.1.2 Market Dynamics
    • 2.1.3 Market Sizing and Forecast
      • 2.1.3.1 North America Diffuse Large B-cell Lymphoma Market, by Country
        • 2.1.3.1.1 U.S.
  • 2.2 Europe
    • 2.2.1 Key Findings
    • 2.2.2 Market Dynamics
    • 2.2.3 Market Sizing and Forecast
      • 2.2.3.1 Europe Diffuse Large B-cell Lymphoma Market, by Country
        • 2.2.3.1.1 Germany
        • 2.2.3.1.2 U.K.
        • 2.2.3.1.3 France
        • 2.2.3.1.4 Italy
  • 2.3 Asia Pacific
    • 2.3.1 Key Findings
    • 2.3.2 Market Dynamics
    • 2.3.3 Market Sizing and Forecast
      • 2.3.3.1 Asia Pacific Diffuse Large B-cell Lymphoma Market, by Country
        • 2.3.3.1.1 China
        • 2.3.3.1.2 Japan

3. Global Diffuse Large B-cell Lymphoma Market: Competitive Landscape and Company Profiles

  • 3.1 Key Strategies and Development
    • 3.1.1 Mergers and Acquisitions
    • 3.1.2 Synergistic Activities
    • 3.1.3 Business Expansions and Funding
    • 3.1.4 Product Launches and Approvals
    • 3.1.5 Other Activities
  • 3.2 Company Profiles
    • 3.2.1 AbbVie Inc.
      • 3.2.1.1 Overview
      • 3.2.1.2 Top Products / Product Portfolio
      • 3.2.1.3 Top Competitors
      • 3.2.1.4 Target Customers/End-Users
      • 3.2.1.5 Key Personnel
      • 3.2.1.6 Analyst View
    • 3.2.2 Merck KGaA
      • 3.2.2.1 Overview
      • 3.2.2.2 Top Products / Product Portfolio
      • 3.2.2.3 Top Competitors
      • 3.2.2.4 Target Customers/End-Users
      • 3.2.2.5 Key Personnel
      • 3.2.2.6 Analyst View
    • 3.2.3 F. Hoffmann-La Roche AG
      • 3.2.3.1 Overview
      • 3.2.3.2 Top Products / Product Portfolio
      • 3.2.3.3 Top Competitors
      • 3.2.3.4 Target Customers/End-Users
      • 3.2.3.5 Key Personnel
      • 3.2.3.6 Analyst View
    • 3.2.4 Johnson & Johnson (Janssen Pharmaceuticals, Inc.)
      • 3.2.4.1 Overview
      • 3.2.4.2 Top Products / Product Portfolio
      • 3.2.4.3 Top Competitors
      • 3.2.4.4 Target Customers/End-Users
      • 3.2.4.5 Key Personnel
      • 3.2.4.6 Analyst View
    • 3.2.5 Denovo Biopharma, Inc.
      • 3.2.5.1 Overview
      • 3.2.5.2 Top Products / Product Portfolio
      • 3.2.5.3 Top Competitors
      • 3.2.5.4 Target Customers/End-Users
      • 3.2.5.5 Key Personnel
      • 3.2.5.6 Analyst View
    • 3.2.6 Calithera Biosciences, Inc.
      • 3.2.6.1 Overview
      • 3.2.6.2 Top Products / Product Portfolio
      • 3.2.6.3 Top Competitors
      • 3.2.6.4 Target Customers/End-Users
      • 3.2.6.5 Key Personnel
      • 3.2.6.6 Analyst View
    • 3.2.7 Biogen Inc.
      • 3.2.7.1 Overview
      • 3.2.7.2 Top Products / Product Portfolio
      • 3.2.7.3 Top Competitors
      • 3.2.7.4 Target Customers/End-Users
      • 3.2.7.5 Key Personnel
      • 3.2.7.6 Analyst View
    • 3.2.8 Autolus Therapeutics plc
      • 3.2.8.1 Overview
      • 3.2.8.2 Top Products / Product Portfolio
      • 3.2.8.3 Top Competitors
      • 3.2.8.4 Target Customers/End-Users
      • 3.2.8.5 Key Personnel
      • 3.2.8.6 Analyst View
    • 3.2.9 Allogene Therapeutics, Inc.
      • 3.2.9.1 Overview
      • 3.2.9.2 Top Products / Product Portfolio
      • 3.2.9.3 Top Competitors
      • 3.2.9.4 Target Customers/End-Users
      • 3.2.9.5 Key Personnel
      • 3.2.9.6 Analyst View
    • 3.2.10 Novartis AG
      • 3.2.10.1 Overview
      • 3.2.10.2 Top Products / Product Portfolio
      • 3.2.10.3 Top Competitors
      • 3.2.10.4 Target Customers/End-Users
      • 3.2.10.5 Key Personnel
      • 3.2.10.6 Analyst View
    • 3.2.11 Miltenyi Biomedicine GmbH
      • 3.2.11.1 Overview
      • 3.2.11.2 Top Products / Product Portfolio
      • 3.2.11.3 Top Competitors
      • 3.2.11.4 Target Customers/End-Users
      • 3.2.11.5 Key Personnel
      • 3.2.11.6 Analyst View
    • 3.2.12 Regeneron Pharmaceuticals, Inc.
      • 3.2.12.1 Overview
      • 3.2.12.2 Top Products / Product Portfolio
      • 3.2.12.3 Top Competitors
      • 3.2.12.4 Target Customers/End-Users
      • 3.2.12.5 Key Personnel
      • 3.2.12.6 Analyst View
    • 3.2.13 Debiopharm International SA
      • 3.2.13.1 Overview
      • 3.2.13.2 Top Products / Product Portfolio
      • 3.2.13.3 Top Competitors
      • 3.2.13.4 Target Customers/End-Users
      • 3.2.13.5 Key Personnel
      • 3.2.13.6 Analyst View
    • 3.2.14 Seagen Inc.
      • 3.2.14.1 Overview
      • 3.2.14.2 Top Products / Product Portfolio
      • 3.2.14.3 Top Competitors
      • 3.2.14.4 Target Customers/End-Users
      • 3.2.14.5 Key Personnel
      • 3.2.14.6 Analyst View
    • 3.2.15 Takeda Pharmaceutical Company Limited
      • 3.2.15.1 Overview
      • 3.2.15.2 Top Products / Product Portfolio
      • 3.2.15.3 Top Competitors
      • 3.2.15.4 Target Customers/End-Users
      • 3.2.15.5 Key Personnel
      • 3.2.15.6 Analyst View

4. Research Methodology

List of Figures

  • Figure: Global Diffuse Large B-cell Lymphoma Market (by Region), $Billion, 2024 and 2035
  • Figure: Global Diffuse Large B-cell Lymphoma Market Key Trends, Analysis

List of Tables

  • Table: Global Diffuse Large B-cell Lymphoma Market Dynamics, Impact Analysis
  • Table: Global Diffuse Large B-cell Lymphoma Market (by Region), $Billion, 2024-2035